Phaseline

Companies › CAMP4 Therapeutics

CAMP4 Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CMP-CPS-001
Antisense oligonucleotide targeting OTC (ornithine transcarbamylase)
OTCPhase 1Healthy VolunteersDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06247670CMP-CPS-001Phase 1Healthy VolunteersMetabolic and endocrineDec 2027

From the company's SEC filings

Cash of $125m on 2026-09-30; operating cash outflow about $43m a year; runway about 35 months at that burn, to Aug 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

OTC (1)

Companies with the same targets

Ultragenyx Pharmaceutical Arcturus Therapeutics iECURE

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.